Xenetic Biosciences (NASDAQ:XBIO) Announces Earnings Results, Beats Estimates By $0.16 EPS

Xenetic Biosciences (NASDAQ:XBIO) released its quarterly earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16, FiscalAI reports. The business had revenue of $1.03 million during the quarter. Xenetic Biosciences had a negative return on equity of 54.56% and a negative net margin of 126.08%.

Xenetic Biosciences Price Performance

XBIO stock traded down $0.09 during midday trading on Wednesday, hitting $2.64. The stock had a trading volume of 34,960 shares, compared to its average volume of 270,393. The business has a 50-day moving average of $3.74 and a two-hundred day moving average of $3.38. The firm has a market cap of $4.07 million, a price-to-earnings ratio of -1.32 and a beta of 2.44. Xenetic Biosciences has a 52-week low of $2.20 and a 52-week high of $13.93.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Xenetic Biosciences currently has a consensus rating of “Reduce”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.